Noxafil Gains Additional Oropharyngeal Candidiasis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.